BioSpace News Archive

The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announces it has entered a collaboration agreement with Eikonizo Therapeutics, Inc., a biotechnology company committed to creating life-changing therapies, to develop inhibitors of histone deacetylase-6 (HDAC6) focused on treating amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease, and other diseases.

RES announced today the acquisition of Applied Ecological Services (AES), one of the nation’s longest-standing ecological restoration firms and a leader in applying the science of ecology to land-use decisions.

Culturally-Centric Life Science Company aggressively accelerates the development of the lead platform StarSense and expand the development of a Rubix LS owned clinical trial site for launching clinical trials.

Biorasi, a leading global full-service contract research organization (CRO), is proud to announce the appointment of dermatologist Lawrence Green, MD, FAAD to the position of Scientific Advisory Board (SAB) member.

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced additional confirmed objective clinical responses from its Phase 1/2 trial of AGEN1181, its next-generation anti-CTLA-4, as monotherapy and in combination with Agenus’ anti-PD-1 balstilimab.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced the award of a grant from The Michael J. Fox Foundation for Parkinson’s Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson’s disease (PD) based on imaging of brain iron.

Echosens, a high-technology company offering the FibroScan family of products, announces the appointment of Jo Massoels as chief marketing officer, bringing to Echosens significant expertise in the medical equipment sector that will be leveraged to expand the market development strategy for the FibroScan suite of products and services.

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company overview at the BIO CEO & Investor Digital Conference, being held virtually on February 16 - 18, 2021

Neovasc, Inc. announced that it has received written notification from the Nasdaq Stock Market LLC notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 pursuant to Nasdaq Listing Rule 5810 for continued listing on the Nasdaq.

Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies, today announced that it has priced its initial public offering (the “IPO”) of 7,354,000 American depositary shares (“ADSs”), at US$19.00 per ADS.